Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 120

1.

Application of Bivalent Bioisostere Concept on Design and Discovery of Potent Opioid Receptor Modulators.

Ma H, Obeng S, Wang H, Zheng Y, Li M, Jali AM, Stevens D, Dewey WL, Selley DE, Zhang Y.

J Med Chem. 2019 Nov 29. doi: 10.1021/acs.jmedchem.9b01767. [Epub ahead of print]

PMID:
31782922
2.

Pharmacological characterization of 17-cyclopropylmethyl-3,14-dihydroxy-4,5-epoxy-6-[(3'-fluoro-4'-pyridyl)acetamido]morphinan (NFP) as a dual selective MOR/KOR ligand with potential applications in treating opioid use disorder.

Zheng Y, Obeng S, Reinecke BA, Chen C, Phansalkar PS, Walentiny DM, Gerk PM, Liu-Chen LY, Selley DE, Beardsley PM, Zhang Y.

Eur J Pharmacol. 2019 Nov 16:172812. doi: 10.1016/j.ejphar.2019.172812. [Epub ahead of print]

PMID:
31743739
3.

Gnal haploinsufficiency causes genomic instability and increased sensitivity to haloperidol.

Khan MM, Xiao J, Hollingsworth TJ, Patel D, Selley DE, Ring TL, LeDoux MS.

Exp Neurol. 2019 Aug;318:61-70. doi: 10.1016/j.expneurol.2019.04.014. Epub 2019 Apr 26.

PMID:
31034808
4.

Characterization of 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(indole-7-carboxamido)morphinan (NAN) as a Novel Opioid Receptor Modulator for Opioid Use Disorder Treatment.

Obeng S, Jali A, Zheng Y, Wang H, Schwienteck KL, Chen C, Stevens DL, Akbarali HI, Dewey WL, Banks ML, Liu-Chen LY, Selley DE, Zhang Y.

ACS Chem Neurosci. 2019 May 15;10(5):2518-2532. doi: 10.1021/acschemneuro.9b00038. Epub 2019 Feb 21.

5.

Design, Synthesis, and Biological Evaluation of the Third Generation 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan (NAP) Derivatives as μ/κ Opioid Receptor Dual Selective Ligands.

Zheng Y, Obeng S, Wang H, Jali AM, Peddibhotla B, Williams DA, Zou C, Stevens DL, Dewey WL, Akbarali HI, Selley DE, Zhang Y.

J Med Chem. 2019 Jan 24;62(2):561-574. doi: 10.1021/acs.jmedchem.8b01158. Epub 2019 Jan 11.

6.

Structure-Activity Relationship Studies of 6α- and 6β-Indolylacetamidonaltrexamine Derivatives as Bitopic Mu Opioid Receptor Modulators and Elaboration of the "Message-Address Concept" To Comprehend Their Functional Conversion.

Obeng S, Wang H, Jali A, Stevens DL, Akbarali HI, Dewey WL, Selley DE, Zhang Y.

ACS Chem Neurosci. 2019 Mar 20;10(3):1075-1090. doi: 10.1021/acschemneuro.8b00349. Epub 2018 Sep 7.

PMID:
30156823
7.

Early adolescent nicotine exposure affects later-life hippocampal mu-opioid receptors activity and morphine reward but not physical dependence in male mice.

Kota D, Alajaji M, Bagdas D, Selley DE, Sim-Selley LJ, Damaj MI.

Pharmacol Biochem Behav. 2018 Oct;173:58-64. doi: 10.1016/j.pbb.2018.08.006. Epub 2018 Aug 17.

8.

Methylation Products of 6β- N-Heterocyclic Substituted Naltrexamine Derivatives as Potential Peripheral Opioid Receptor Modulators.

Zheng Y, Obeng S, Wang H, Stevens DL, Komla E, Selley DE, Dewey WL, Akbarali HI, Zhang Y.

ACS Chem Neurosci. 2018 Dec 19;9(12):3028-3037. doi: 10.1021/acschemneuro.8b00234. Epub 2018 Jul 23.

PMID:
30001114
9.

Differential Tolerance to FTY720-Induced Antinociception in Acute Thermal and Nerve Injury Mouse Pain Models: Role of Sphingosine-1-Phosphate Receptor Adaptation.

Sim-Selley LJ, Wilkerson JL, Burston JJ, Hauser KF, McLane V, Welch SP, Lichtman AH, Selley DE.

J Pharmacol Exp Ther. 2018 Sep;366(3):509-518. doi: 10.1124/jpet.118.248260. Epub 2018 Jun 26.

10.

Amphetamine maintenance differentially modulates effects of cocaine, methylenedioxypyrovalerone (MDPV), and methamphetamine on intracranial self-stimulation and nucleus accumbens dopamine in rats.

Johnson AR, Banks ML, Selley DE, Negus SS.

Neuropsychopharmacology. 2018 Jul;43(8):1753-1762. doi: 10.1038/s41386-018-0071-3. Epub 2018 Apr 19.

11.
12.

Δ9-Tetrahydrocannabinol Experience Influences ΔFosB and Downstream Gene Expression in Prefrontal Cortex.

Lazenka MF, Kang M, De DD, Selley DE, Sim-Selley LJ.

Cannabis Cannabinoid Res. 2017 Aug 1;2(1):224-234. doi: 10.1089/can.2017.0022. eCollection 2017.

13.

Nanoconjugated NAP as a Potent and Periphery Selective Mu Opioid Receptor Modulator To Treat Opioid-Induced Constipation.

Xu GG, Zolotarskaya OY, Williams DA, Yuan Y, Selley DE, Dewey WL, Akbarali HI, Yang H, Zhang Y.

ACS Med Chem Lett. 2016 Nov 21;8(1):78-83. doi: 10.1021/acsmedchemlett.6b00382. eCollection 2017 Jan 12.

14.

Cannabinoid Receptor Interacting Protein 1a Competition with β-Arrestin for CB1 Receptor Binding Sites.

Blume LC, Patten T, Eldeeb K, Leone-Kabler S, Ilyasov AA, Keegan BM, O'Neal JE, Bass CE, Hantgan RR, Lowther WT, Selley DE, Howlett AL.

Mol Pharmacol. 2017 Feb;91(2):75-86. doi: 10.1124/mol.116.104638. Epub 2016 Nov 28.

15.

Exploration of bivalent ligands targeting putative mu opioid receptor and chemokine receptor CCR5 dimerization.

Arnatt CK, Falls BA, Yuan Y, Raborg TJ, Masvekar RR, El-Hage N, Selley DE, Nicola AV, Knapp PE, Hauser KF, Zhang Y.

Bioorg Med Chem. 2016 Nov 15;24(22):5969-5987. doi: 10.1016/j.bmc.2016.09.059. Epub 2016 Sep 26.

16.

Cannabinoid receptor interacting protein suppresses agonist-driven CB1 receptor internalization and regulates receptor replenishment in an agonist-biased manner.

Blume LC, Leone-Kabler S, Luessen DJ, Marrs GS, Lyons E, Bass CE, Chen R, Selley DE, Howlett AC.

J Neurochem. 2016 Nov;139(3):396-407. doi: 10.1111/jnc.13767. Epub 2016 Sep 26.

17.

Stratification of Cannabinoid 1 Receptor (CB1R) Agonist Efficacy: Manipulation of CB1R Density through Use of Transgenic Mice Reveals Congruence between In Vivo and In Vitro Assays.

Grim TW, Morales AJ, Gonek MM, Wiley JL, Thomas BF, Endres GW, Sim-Selley LJ, Selley DE, Negus SS, Lichtman AH.

J Pharmacol Exp Ther. 2016 Nov;359(2):329-339. Epub 2016 Aug 17.

18.

Discriminative Stimulus Properties of the Endocannabinoid Catabolic Enzyme Inhibitor SA-57 in Mice.

Owens RA, Ignatowska-Jankowska B, Mustafa M, Beardsley PM, Wiley JL, Jali A, Selley DE, Niphakis MJ, Cravatt BF, Lichtman AH.

J Pharmacol Exp Ther. 2016 Aug;358(2):306-14. doi: 10.1124/jpet.115.229492. Epub 2016 Jun 15.

19.

6β-N-Heterocyclic Substituted Naltrexamine Derivative BNAP: A Peripherally Selective Mixed MOR/KOR Ligand.

Williams DA, Zheng Y, David BG, Yuan Y, Zaidi SA, Stevens DL, Scoggins KL, Selley DE, Dewey WL, Akbarali HI, Zhang Y.

ACS Chem Neurosci. 2016 Aug 17;7(8):1120-9. doi: 10.1021/acschemneuro.6b00075. Epub 2016 Jun 15.

20.

Pharmacological characterization of repeated administration of the first generation abused synthetic cannabinoid CP47,497.

Grim TW, Samano KL, Ignatowska-Jankowska B, Tao Q, Sim-Selly LJ, Selley DE, Wise LE, Poklis A, Lichtman AH.

J Basic Clin Physiol Pharmacol. 2016 May 1;27(3):217-28. doi: 10.1515/jbcpp-2015-0118.

21.

Central HIV-1 Tat exposure elevates anxiety and fear conditioned responses of male mice concurrent with altered mu-opioid receptor-mediated G-protein activation and β-arrestin 2 activity in the forebrain.

Hahn YK, Paris JJ, Lichtman AH, Hauser KF, Sim-Selley LJ, Selley DE, Knapp PE.

Neurobiol Dis. 2016 Aug;92(Pt B):124-36. doi: 10.1016/j.nbd.2016.01.014. Epub 2016 Feb 1.

22.

Early adolescent nicotine exposure affects later-life cocaine reward in mice.

Alajaji M, Lazenka MF, Kota D, Wise LE, Younis RM, Carroll FI, Levine A, Selley DE, Sim-Selley LJ, Damaj MI.

Neuropharmacology. 2016 Jun;105:308-317. doi: 10.1016/j.neuropharm.2016.01.032. Epub 2016 Jan 22.

PMID:
26808314
23.

Efficacy of Hybrid Tetrahydrobenzo[d]thiazole Based Aryl Piperazines D-264 and D-301 at D₂ and D₃ Receptors.

Zhen J, Antonio T, Jacob JC, Grandy DK, Reith MEA, Dutta AK, Selley DE.

Neurochem Res. 2016 Feb;41(1-2):328-339. doi: 10.1007/s11064-015-1808-6. Epub 2015 Dec 31.

24.

17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-(4'-pyridylcarboxamido)morphinan (NAP) Modulating the Mu Opioid Receptor in a Biased Fashion.

Zhang Y, Williams DA, Zaidi SA, Yuan Y, Braithwaite A, Bilsky EJ, Dewey WL, Akbarali HI, Streicher JM, Selley DE.

ACS Chem Neurosci. 2016 Mar 16;7(3):297-304. doi: 10.1021/acschemneuro.5b00245. Epub 2016 Jan 8.

25.

Metabolic Interplay between Astrocytes and Neurons Regulates Endocannabinoid Action.

Viader A, Blankman JL, Zhong P, Liu X, Schlosburg JE, Joslyn CM, Liu QS, Tomarchio AJ, Lichtman AH, Selley DE, Sim-Selley LJ, Cravatt BF.

Cell Rep. 2015 Aug 4;12(5):798-808. doi: 10.1016/j.celrep.2015.06.075. Epub 2015 Jul 23.

26.

Role of Dopamine Type 1 Receptors and Dopamine- and cAMP-Regulated Phosphoprotein Mr 32 kDa in Δ9-Tetrahydrocannabinol-Mediated Induction of ΔFosB in the Mouse Forebrain.

Lazenka MF, Tomarchio AJ, Lichtman AH, Greengard P, Flajolet M, Selley DE, Sim-Selley LJ.

J Pharmacol Exp Ther. 2015 Sep;354(3):316-27. doi: 10.1124/jpet.115.224428. Epub 2015 Jun 22.

27.

Full Fatty Acid Amide Hydrolase Inhibition Combined with Partial Monoacylglycerol Lipase Inhibition: Augmented and Sustained Antinociceptive Effects with Reduced Cannabimimetic Side Effects in Mice.

Ghosh S, Kinsey SG, Liu QS, Hruba L, McMahon LR, Grim TW, Merritt CR, Wise LE, Abdullah RA, Selley DE, Sim-Selley LJ, Cravatt BF, Lichtman AH.

J Pharmacol Exp Ther. 2015 Aug;354(2):111-20. doi: 10.1124/jpet.115.222851. Epub 2015 May 21.

28.

Design, syntheses, and pharmacological characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan analogues as opioid receptor ligands.

Yuan Y, Zaidi SA, Stevens DL, Scoggins KL, Mosier PD, Kellogg GE, Dewey WL, Selley DE, Zhang Y.

Bioorg Med Chem. 2015 Apr 15;23(8):1701-15. doi: 10.1016/j.bmc.2015.02.055. Epub 2015 Mar 6.

29.

Cannabinoid receptor-interacting protein 1a modulates CB1 receptor signaling and regulation.

Smith TH, Blume LC, Straiker A, Cox JO, David BG, McVoy JR, Sayers KW, Poklis JL, Abdullah RA, Egertová M, Chen CK, Mackie K, Elphick MR, Howlett AC, Selley DE.

Mol Pharmacol. 2015 Apr;87(4):747-65. doi: 10.1124/mol.114.096495. Epub 2015 Feb 5.

30.

Cannabinoid receptor interacting protein (CRIP1a) attenuates CB1R signaling in neuronal cells.

Blume LC, Eldeeb K, Bass CE, Selley DE, Howlett AC.

Cell Signal. 2015 Mar;27(3):716-726. doi: 10.1016/j.cellsig.2014.11.006. Epub 2014 Nov 17.

31.

Effects of the novel, selective and low-efficacy mu opioid receptor ligand NAQ on intracranial self-stimulation in rats.

Altarifi AA, Yuan Y, Zhang Y, Selley DE, Negus SS.

Psychopharmacology (Berl). 2015 Feb;232(4):815-24. doi: 10.1007/s00213-014-3719-7. Epub 2014 Sep 3.

32.

Delta FosB and AP-1-mediated transcription modulate cannabinoid CB₁ receptor signaling and desensitization in striatal and limbic brain regions.

Lazenka MF, David BG, Lichtman AH, Nestler EJ, Selley DE, Sim-Selley LJ.

Biochem Pharmacol. 2014 Oct 1;91(3):380-9. doi: 10.1016/j.bcp.2014.07.024. Epub 2014 Aug 2.

33.

ABHD6 blockade exerts antiepileptic activity in PTZ-induced seizures and in spontaneous seizures in R6/2 mice.

Naydenov AV, Horne EA, Cheah CS, Swinney K, Hsu KL, Cao JK, Marrs W, Blankman JL, Tu S, Cherry AE, Fung S, Wen A, Li W, Saporito MS, Selley DE, Cravatt BF, Oakley JC, Stella N.

Neuron. 2014 Jul 16;83(2):361-371. doi: 10.1016/j.neuron.2014.06.030.

34.

Prolonged monoacylglycerol lipase blockade causes equivalent cannabinoid receptor type 1 receptor-mediated adaptations in fatty acid amide hydrolase wild-type and knockout mice.

Schlosburg JE, Kinsey SG, Ignatowska-Jankowska B, Ramesh D, Abdullah RA, Tao Q, Booker L, Long JZ, Selley DE, Cravatt BF, Lichtman AH.

J Pharmacol Exp Ther. 2014 Aug;350(2):196-204. doi: 10.1124/jpet.114.212753. Epub 2014 May 21.

35.

Mutation of putative GRK phosphorylation sites in the cannabinoid receptor 1 (CB1R) confers resistance to cannabinoid tolerance and hypersensitivity to cannabinoids in mice.

Morgan DJ, Davis BJ, Kearn CS, Marcus D, Cook AJ, Wager-Miller J, Straiker A, Myoga MH, Karduck J, Leishman E, Sim-Selley LJ, Czyzyk TA, Bradshaw HB, Selley DE, Mackie K.

J Neurosci. 2014 Apr 9;34(15):5152-63. doi: 10.1523/JNEUROSCI.3445-12.2014.

36.

Predicting the molecular interactions of CRIP1a-cannabinoid 1 receptor with integrated molecular modeling approaches.

Ahmed MH, Kellogg GE, Selley DE, Safo MK, Zhang Y.

Bioorg Med Chem Lett. 2014 Feb 15;24(4):1158-65. doi: 10.1016/j.bmcl.2013.12.119. Epub 2014 Jan 8.

37.

Combined antiproliferative effects of the aminoalkylindole WIN55,212-2 and radiation in breast cancer cells.

Emery SM, Alotaibi MR, Tao Q, Selley DE, Lichtman AH, Gewirtz DA.

J Pharmacol Exp Ther. 2014 Feb;348(2):293-302. doi: 10.1124/jpet.113.205120. Epub 2013 Nov 20. Erratum in: J Pharmacol Exp Ther. 2016 Jun;357(3):619.

38.

Design, synthesis, and biological evaluation of 14-heteroaromatic-substituted naltrexone derivatives: pharmacological profile switch from mu opioid receptor selectivity to mu/kappa opioid receptor dual selectivity.

Yuan Y, Zaidi SA, Elbegdorj O, Aschenbach LC, Li G, Stevens DL, Scoggins KL, Dewey WL, Selley DE, Zhang Y.

J Med Chem. 2013 Nov 27;56(22):9156-69. doi: 10.1021/jm4012214. Epub 2013 Nov 7.

39.

ΔFosB induction correlates inversely with CB₁ receptor desensitization in a brain region-dependent manner following repeated Δ⁹-THC administration.

Lazenka MF, Selley DE, Sim-Selley LJ.

Neuropharmacology. 2014 Feb;77:224-33. doi: 10.1016/j.neuropharm.2013.09.019. Epub 2013 Sep 30.

42.

Sphingosine lysolipids in the CNS: endogenous cannabinoid antagonists or a parallel pain modulatory system?

Selley DE, Welch SP, Sim-Selley LJ.

Life Sci. 2013 Aug 14;93(5-6):187-93. doi: 10.1016/j.lfs.2013.06.004. Epub 2013 Jun 16. Review.

43.

Opioid receptor selectivity profile change via isosterism for 14-O-substituted naltrexone derivatives.

Zhang Y, Elbegdorj O, Yuan Y, Beletskaya IO, Selley DE.

Bioorg Med Chem Lett. 2013 Jul 1;23(13):3719-22. doi: 10.1016/j.bmcl.2013.05.027. Epub 2013 May 16.

44.

A Bivalent Ligand Targeting the Putative Mu Opioid Receptor and Chemokine Receptor CCR5 Heterodimers: Binding Affinity versus Functional Activities.

Yuan Y, Arnatt CK, El-Hage N, Dever SM, Jacob JC, Selley DE, Hauser KF, Zhang Y.

Medchemcomm. 2013 May 1;4(5):847-851.

45.

Repeated low-dose administration of the monoacylglycerol lipase inhibitor JZL184 retains cannabinoid receptor type 1-mediated antinociceptive and gastroprotective effects.

Kinsey SG, Wise LE, Ramesh D, Abdullah R, Selley DE, Cravatt BF, Lichtman AH.

J Pharmacol Exp Ther. 2013 Jun;345(3):492-501. doi: 10.1124/jpet.112.201426. Epub 2013 Feb 14.

46.

Striatal CB1 and D2 receptors regulate expression of each other, CRIP1A and δ opioid systems.

Blume LC, Bass CE, Childers SR, Dalton GD, Roberts DC, Richardson JM, Xiao R, Selley DE, Howlett AC.

J Neurochem. 2013 Mar;124(6):808-20. doi: 10.1111/jnc.12139. Epub 2013 Jan 31.

47.

Design, synthesis, and biological evaluation of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan derivatives as peripheral selective μ opioid receptor Agents.

Yuan Y, Elbegdorj O, Chen J, Akubathini SK, Zhang F, Stevens DL, Beletskaya IO, Scoggins KL, Zhang Z, Gerk PM, Selley DE, Akbarali HI, Dewey WL, Zhang Y.

J Med Chem. 2012 Nov 26;55(22):10118-29. doi: 10.1021/jm301247n. Epub 2012 Nov 9.

48.

Sphingosine-1-phosphate receptors as emerging targets for treatment of pain.

Welch SP, Sim-Selley LJ, Selley DE.

Biochem Pharmacol. 2012 Dec 15;84(12):1551-62. doi: 10.1016/j.bcp.2012.08.010. Epub 2012 Aug 16. Review.

PMID:
22971335
49.

Brain regional differences in CB1 receptor adaptation and regulation of transcription.

Lazenka MF, Selley DE, Sim-Selley LJ.

Life Sci. 2013 Mar 19;92(8-9):446-52. doi: 10.1016/j.lfs.2012.08.023. Epub 2012 Aug 24. Review.

50.

Characterization of 6α- and 6β-N-heterocyclic substituted naltrexamine derivatives as novel leads to development of mu opioid receptor selective antagonists.

Yuan Y, Li G, He H, Stevens DL, Kozak P, Scoggins KL, Mitra P, Gerk PM, Selley DE, Dewey WL, Zhang Y.

ACS Chem Neurosci. 2011 Jul 20;2(7):346-51. doi: 10.1021/cn2000348. Epub 2011 May 6.

Supplemental Content

Loading ...
Support Center